Our Company

Driven by science and discovery, connected by a passion to help patients

From Concept to Commercialization,
We Journey With You

We meet our partners where they are in the product life cycle and enable their work with our array of technology platforms, end-to-end capabilities and industry insights so they can bring their original concepts to commercialization.

Our Story

Building a first-of-its kind offering of enabling technologies and end-to-end capabilities to advance the work of the entire cell and gene therapy industry

2017 - Founded. David Hallal, Mitchell Finer and Vikas Sinha ask the question: what could be revolutionary in the next 30 to 50 years? ElevateBio formed in stealth mode.
September 2018. AlloVir, a leading innovator of allogeneic, multi-virus, t-cell immunotherapies, is added as a portfolio company.
May 2019. ElevateBio raises $150M in Series A financing, officially launching to create and operate a portfolio of highly innovative cell and gene therapy companies.
July 2019. Massachusetts General Hospital & Elevate announce strategic partnership.
October 2019. ElevateBio establishes and launches HighPassBio, a company dedicated to advancing novel targeted T cell immunotherapies initially developed by researchers at Fred Hutchinson Cancer Research Center.
January 2020. ElevateBio BaseCamp process development labs open, providing the tools and environment to accelerate cell and gene therapies.
March 2020. ElevateBio raises $170M in series B financing.
November 2020. LifeEdit, with it's novel Gene editing platform, is added as a portfolio company.
April 2021. BaseCamp is selected as 2021 Facility of the Year Award for Operational Excellence.
June 2021. Boston Children's Hospital and ElevateBio announce 5 Year Cell and Gene Therapy Collaboration.
October 2021. LifeEdit acquisition completed as ElevateBio accelerates genome editing platform.
October 2021. LifeEdit acquisition completed as ElevateBio accelerates genome editing platform.

Meet Our Team
of Industry Experts

Our team of world-class scientists, builders and operators use their deep industry expertise to equip our partners every step of the way.

Elevated Insights

Learn more about ElevateBio and how our team of industry experts are enabling the cell and gene therapy industry

January 2023

Reflecting on ElevateBio's First Five Years

From our Chairman and CEO, David Hallal

Read More

June 2022

ElevateBio's Lentiviral Vector Platform: Right the first time

By: Mercedes Segura, Vice President, Process Development, ElevateBio, Dawn Maier, Vice President, Emerging Technologies, ElevateBio, and Bojiao Yin, Director of Vector Process Development, ElevateBio

Read More

Partner With Us

Wherever you are in your cell and gene therapy (CGT) product life cycle, we come alongside you to strengthen and accelerate the development of life-transformative CGTs.